San Diego, USA-based Neurocrine Biosciences today announced the launch of its Crenessity (crinecerfont) in the USA.

Epitopea partners with Genevant Sciences to develop RNA-based cancer immunotherapies targeting proprietary tumor antigens.

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

Zealand Pharma faces a setback as the FDA issues a complete response letter for glepaglutide, requiring a new Phase III trial ...

Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, ...

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...

Swiss pharma giant Novartis (NOVN: VX) is to shut two sites belonging to its MorphoSys unit. The facilities in Munich, ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) today recommending Pedmarqsi ...

The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in ...

The US Department of Justice (DoJ) unveiled a suit Wednesday accusing CVS, the nation's largest pharmacy chain, with more ...